- Assistant Professor of Pharmaceutical Sciences
Dr. Xinwen Wang received training in pharmacokinetics and metabolomics at China Pharmaceutical University and with subsequent training in pharmacogenomics and proteomics at University of Florida and University of Michigan during her Ph.D. work. During her postdoctoral training in translational sciences, Dr. Wang developed a strong appreciation for applying novel knowledge from basic research to address critical clinical needs. This broad training experience has enabled Dr. Wang to apply integrated tools to study the interindividual variability in disease susceptibility and drug responses, and also spanned the translational spectrum of her research from basic discovery to clinical investigation. Dr. Wang is a recipient of Pre-K award in translational science and has been highlighted as an emerging scientific talent by a prestigious journal in the field of pharmacology “Drug Metabolism and Disposition”.
Area of Expertise/Research Interests
Dr. Wang’s laboratory focuses on applying pharmaco-omics tools to identify both genetic and non-genetic factors contributing to the interindividual variability related to disease risks and drug therapies for:
- Cardiovascular disease
- Metabolic syndrome
- Neurological disorder
The objective of Dr. Wang’s lab is to advance understanding of molecular basis for the interindividual variability in disease susceptibility and drug response, and to eventually optimize the treatments for patients through genotype, prototype and metabotype guided precision pharmacotherapy.
- Postdoc in Translational sciences, Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, 2015-2020
- Ph.D. in Pharmacokinetics, China Pharmaceutical University, Nanjing, China, 2009-2015
Trainings during Ph.D.
- Proteomics, University of Michigan, Ann Arbor, MI, 2013-2015
- Pharmacogenomics, University of Florida, Gainesville, FL, 2012-2013
- Metabolomics, China Pharmaceutical University, Nanjing China, 2009-2012
- B.S. in Pharmacology, China Pharmaceutical University, Nanjing, China, 2005-2009
- Pharmacodynamics and Pharmacokinetics (PD/PK)
- Wang X, He B, Shi J, Li Q and Zhu HJ, Comparative Proteomics Analysis of Human Liver Microsomes and S9 Fractions, Drug Metab Dispos. 2020, 48(1): 31-40
- Wang X, Shi J, Zhu HJ, Functional Study of Carboxylesterase1 Protein Isoforms, Proteomics, 2019, 19 (4): e1800288
- Wang X, Rida N, Shi J, Wu A, Bleske B, Zhu H. A comprehensive functional assessment of carboxylesterase 1 nonsynonymous polymorphisms. Drug Metab Dispos. 2017, 45(11): 1149-1155
- Wang X, Liang Y, Liu L, Shi J, and Zhu HJ. Targeted absolute quantitative proteomics with SILAC internal standards and unlabeled full-length protein calibrators (TAQSI). Rapid Commun. Mass Spectrom. 2016, 30: 1–9 [Cover Story]
- Sanford JC*, Wang X*, Shi J, Barrie ES, Wang DX, Zhu HJ, Sadee W. Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus. Pharmacogenet and Genomics, 2016, 26(5): 197-207 [*Co-first authors]